Michigan Medicine - University of Michigan Jul 8 2025 A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment. Treatments such as enzalutamide, which is an androgen receptor pathway inhibitor (ARPI), are standard of care for advanced prostate cancer. While many patients have long-term good response to the drugs, some will derive no benefit whatsoever.